India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...
Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...
Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.
Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...
Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.
To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties ...
Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...
With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...
Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...
CCI fines Goldman Sachs for undisclosed investment in Biocon, highlighting need for compliance with competition laws in ...
Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...
Biocon share price surged 4.5% during Monday's session following the clearance from the US Food and Drug Administration (US ...